Revonco: Transforming Cancer Care in the Middle East with Multi-Cancer Early Detection
We are thrilled to unveil a groundbreaking advancement in cancer screening with the launch our Multi-Cancer Early Detection, Revonco, the first precision diagnosis product specifically designed for the unique Middle Eastern genetic background.
This cutting-edge blood test is set to revolutionize the region’s approach to cancer detection and save thousands of lives each year.
🎯 Early Cancer Detection Redefined
The Revonco Multi-Cancer Early Detection is an unparalleled breakthrough in the fight against cancer. By utilizing state-of-the-art technology and leveraging the latest advances in Generative-AI and Multiomics, our test can identify the presence of multiple cancer types at their earliest stages, even before symptoms manifest. This early detection capability plays a pivotal role in enhancing treatment outcomes and significantly increasing the survival rates of patients across the Middle East.
💡 How it Works
When cells die, they release fragments of their DNA called cell-free DNA (cfDNA) into the bloodstream. Billions of cfDNA in a blood sample provide a snapshot of what’s happening in various organs. In people with cancer, some of these cfDNA fragments come from cancer cells. Revonco identifies the specific cfDNA fragments originating from cancer cells among billions of cfDNA fragments and detects the presence of cancer.
You wonder, when all cells have the same DNA and will have the same throughout life, how can Revonco find differences in the DNA to find cancer? Each cell in the body has the same DNA sequence, but what sets them apart are the epigenetic markers which are like cellular control switches. These markers play a role in a cell’s behavior, including whether it becomes cancerous. Using advanced AI, Revonco sifts through the epigenetic markers in billions of DNA fragments that are shed into the bloodstream to find a few that can distinguish between normal cells and those from cancerous cells. Revonco can detect a variety of cancers, not just one cancer, that collectively contribute to more than 90% of all cancer mortalities when as few as 1 in 10,000 cfDNA comes from cancer cells.
🧬 The First of its kind that is tailored for Middle Eastern Genetics
A cfDNA based test, a.k.a. liquid biopsy, that is designed based on data from western populations, has limited performance when used in another genetic population like the Middle East. One of the key factors that set the Revonco Multi-Cancer Early Detection apart is its optimization for the genetic diversity found in the Middle Eastern population. With our proprietary AI model and its dedicated focus on the Middle Eastern genetic landscape, we can offer unparalleled precision and reliability in detecting various types of cancer.
👥 Saving Lives Through Early Intervention
The impact of early cancer detection cannot be overstated. By detecting cancer at its early stages and before it has a chance to spread, patients have a significantly higher chance of successful treatment and recovery. The Revonco Multi-Cancer Early Detection empowers physicians to identify cancer in its earliest phases, allowing for timely and targeted interventions that can prevent the disease’s progression and save countless lives*.
💪 Empowering Healthcare Professionals
Revonco is not just a test; it represents a paradigm shift in how healthcare professionals tackle cancer in the Middle East. With the ability to identify multiple types of cancer with a blood test at their earliest stages, even before symptoms manifest, Revonco enables timely and targeted interventions*. It vastly improves treatment outcomes and allows for less invasive and more effective treatment options, not only reducing the physical and emotional burden on patients but also optimizes healthcare resources and reduces overall costs.
🌍 A Regional Health Revolution
The release of Revonco Multi-Cancer Early Detection marks the beginning of a new chapter in cancer care for the Middle East. With the potential to prevent countless cases of late-stage cancer and dramatically improve survival rates, Revonco has the capacity to transform the region’s healthcare landscape.
As we move forward, we extend our deepest gratitude to the dedicated researchers, engineers, and patients who have contributed to the development of this groundbreaking test. Together, we envision a future where cancer is no longer a life-threatening condition, and every individual in the Middle East can lead a healthier and happier life.
To learn more about Multi-Cancer Early Detection and pilot it in your clinic or use it in your research, visit detectiome.com/revonco. Join us on this transformative journey as we pave the way for a healthier Middle East. Together, we can rewrite the cancer story and bring hope to countless lives.
* Revonco is available for Research Use Only (RUO) in the UAE.
